Thomas O Jemielita

12PUBLICATIONS
82CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsiesAllergyPharmacogenomicsDiagnostic radiography
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 01, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

|Apr 11, 2026
Belzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control arm.

W Marston Linehan, Thomas Jemielita, Jerry Cornell

|Jun 11, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

|Mar 13, 2025
Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective.

Jie Chen, Lei Nie, Shiowjen Lee

|Feb 14, 2025
Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective.

Jie Chen, Susan Gruber, Hana Lee

|Jan 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.

Jason J Luke, Randy F Sweis, J Randolph Hecht

Pageof 2

Frequent Collaborators

2 joint publications

Jie Chen

2 joint publications

Mark van der Laan

2 joint publications

Haitao Chu

2 joint publications

Susan Gruber